Entera Bio (ENTX) Change in Accured Expenses (2021 - 2026)
Entera Bio (ENTX) recorded quarterly Change in Accured Expenses of -$2000.0 in Q1 2026, down 100.98% on a QoQ basis from $204000.0 in Q4 2025, and down 100.23% year-over-year from $886000.0 in Q1 2025.
Entera Bio (ENTX) Change in Accured Expenses (2021 - 2026) Analysis & Trends
Entera Bio has disclosed Change in Accured Expenses across 6 years of filings, most recently posting -$2000.0 for Q1 2026.
- Quarterly Change in Accured Expenses fell 100.23% year-over-year to -$2000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $156000.0 (down 85.3% YoY) and the FY2025 annual result came in at $1.0 million, up 414.29% from the prior year.
- Change in Accured Expenses retreated to -$2000.0 in Q1 2026, from $204000.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $886000.0 in Q1 2025 and troughed at -$808000.0 in Q1 2022.
- A 5-year average of -$52117.6 and a median of $28000.0 in 2024 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses slumped 2106.9% — and 2025, when it surged 3064.29%.
- Tracing ENTX's Change in Accured Expenses over 5 years: stood at $581000.0 in 2022, then slumped by 213.94% to -$662000.0 in 2023, then jumped by 147.13% to $312000.0 in 2024, then sank by 34.62% to $204000.0 in 2025, then sank by 100.98% to -$2000.0 in 2026.
- Business Quant data shows ENTX's Change in Accured Expenses at -$2000.0 in Q1 2026, $204000.0 in Q4 2025, and -$77000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 931,000.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Entera Bio | 57.79 Mn | 53.65 Mn | - | -2,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,000.00 |
| Mar 31, 2026 | -2,000.00 |
| Dec 31, 2025 | 204,000.00 |
| Dec 31, 2025 | 204,000.00 |
| Sep 30, 2025 | -77,000.00 |
| Sep 30, 2025 | -77,000.00 |
| Jun 30, 2025 | 31,000.00 |
| Jun 30, 2025 | 31,000.00 |
| Mar 31, 2025 | 886,000.00 |
| Mar 31, 2025 | 886,000.00 |
| Dec 31, 2024 | 312,000.00 |
| Dec 31, 2024 | 312,000.00 |
| Sep 30, 2024 | -305,000.00 |
| Sep 30, 2024 | -305,000.00 |
| Jun 30, 2024 | 168,000.00 |
| Jun 30, 2024 | 168,000.00 |
| Mar 31, 2024 | 28,000.00 |
| Mar 31, 2024 | 28,000.00 |
| Dec 31, 2023 | -662,000.00 |
| Dec 31, 2023 | -662,000.00 |